AB0176 THE ROLE OF IL-6 IN PREDICTING INFLAMMATORY ACTIVITY BASED ON ULTRASONOGRAPHIC (US) EVIDENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB BIOSIMILAR (ACELLBIA «BIOCAD») THERAPY
| Autor: | A. Avdeeva, O. Alekseeva, V. Rybakova, E. Nasonov |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of the Rheumatic Diseases. 81:1217.2-1217 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2022-eular.2273 |
| Popis: | Background:ObjectivesTo assess the role of laboratory markers in predicting the persistence of inflammatory activity according to US evidence in patients with RA during therapy with a rituximab biosimilar (RTX) – Acellbia.Methods20 RA pts (18 woman, Me;IQR age 61.5[54-66.5] years, disease duration 39.5[20-84] months, mean DAS 28 5.6[4.9-6.8]) received two intravenous RTX infusions (600 mg №2) in combination with DMARDs and glucocorticoids. Ultrasound with gray scale (GS) and power Doppler (PD) were performed at baseline, 12, 24 weeks after initiation of therapy. The wrist, MCP2, MCP3, PIP2, PIP3, MTP2 and MTP5 joints of the clinically dominant side were examined by US according to the European League Against Rheumatism (EULAR) guidelines. ESAOTE MyLabTwice and GE Logiq 9 US machines with 13–18 MHz-transducer were used. The levels of IL-1b, IL-1Рa, IL-2,-4,-5,-6,-7,-8,-9,-10,-12,-13,-15,-17, Eotaxin, FGF-basic, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, VEGF (pg/ml) were tested by multiplex technology xMAP at baseline and weeks 12 and 24 after the first infusion of RTX.ResultsAfter 24 weeks of RTX therapy values DAS 28 was 4.1 [3.1-4.7]; DAS 28 remission/low disease activity was achieved in 8 (40%) pts, while RTX failure based on EULAR response was documented in 3 (15%) pts. The baseline value of PD was 2.0 [1.0–3.5]; the proportions of PD(+) and PD(−) patients were 65% and 35%, respectively. After 24 weeks of therapy, the PD value was 0.5 [0.0–2.0] points; active inflammation persisted in 7 (35%) patients, pAccording to the ROC analysis, it was found that the basal level of IL-6 more than 100.0 pg/ml is associated with the preservation of inflammatory activity according to PD by the 24th week of therapy with a sensitivity of 85% and a specificity of 62% (AUC = 0.78, 95% CI 0.57–0.99).ConclusionIL-6 is the most promising marker for predicting persistent inflammatory activity according to PD in patients with RA on the RTX biosimilar therapy, other analyzed parameters have worse sensitivity and specificity.Disclosure of InterestsNone declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|